Sustained Viral Response in Chronic Hepatitis B Patients Who Achieved HBeAg Seroncongversion After Interferon Therapy
Sustained Viral Response in Chronic Hepatitis B Patients Who Achieved HBeAg Seroncongversion After Interferon Therapy
Chronic hepatitis B (CHB) is a serious liver disease worldwide, and the leading cause of
 cirrhosis and hepatocellular carcinoma (HCC). HBeAg seroconversion is considered to be the
 satisfied endpoint of antiviral therapy in HBeAg-positive chronic hepatitis B patients.
 However, HBV reaction, even reverse back to HBeAg positive and clinical relapse could occur
 in some patients who achieved HBeAg seronconversion by interferon treatment. In this study,
 the long-term efficacy of interferon therapy in HBeAg positive patients achieved HBeAg
 seronconversion after interferon treatment and the factors associated with viral and clinical
 relapse will be observed.
HBeAg positive chronic hepatitis B patients achieved HBeAg seronconversion by interferon
 treatment will be enrolled and observed for 156 weeks. Serum HBV DNA, HBsAg, anti-HBs, HBeAg,
 and anti-HBe will be measured every 3 months during the observation period, liver function
 tests were performed every 3 months also. The liver ultrasonic examination would be taken
 every 3-6 months. The primary endpoint is sustained viral response, and secondary endpoints
 is HBV DNA reaction and clinical relapse defined as virla relapse with abnormal ALT during
 observation period.
Inclusion Criteria:

 -  patients who achieved HBeAg seroconversion by interferon treatment.

 Exclusion Criteria:

 -  Active consumption of alcohol and/or drugs

 -  Co-infection with human immunodeficiency virus, hepatitis C virus, or hepatitis D
 virus

 -  History of autoimmune hepatitis

 -  Psychiatric disease

 -  Evidence of neoplastic diseases of the liver